stockportfolio.pro
Krystal Biotech, Inc. P/E Ratio 2016–2025
Krystal Biotech, Inc. (KRYS) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -21.5%/yr over 9 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 36.04 | -31.0% |
| FY 2024 | 52.22 | -83.6% |
| FY 2023 | 318.10 | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
Source: Krystal Biotech, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Krystal Biotech, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeKrystal Biotech, Inc. — frequently asked questions
What is Krystal Biotech, Inc.'s price-to-earnings ratio?
Krystal Biotech, Inc. (KRYS) reported price-to-earnings ratio of 36.04 for fiscal year 2025, per its SEC filings.
How has Krystal Biotech, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2016 and 2025, KRYS's price-to-earnings ratio declined at roughly 21.5% per year (compound annual rate), from 318.10 to 36.04.
Where does this data come from?
Figures are computed from Krystal Biotech, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.